US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
US4474893A
(en)
|
1981-07-01 |
1984-10-02 |
The University of Texas System Cancer Center |
Recombinant monoclonal antibodies
|
US4444878A
(en)
|
1981-12-21 |
1984-04-24 |
Boston Biomedical Research Institute, Inc. |
Bispecific antibody determinants
|
IT1190891B
(it)
|
1982-06-24 |
1988-02-24 |
Anic Spa |
Metodo per la sintesi in fase solida di polipeptidi retroinvertiti
|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4757006A
(en)
|
1983-10-28 |
1988-07-12 |
Genetics Institute, Inc. |
Human factor VIII:C gene and recombinant methods for production
|
US4965199A
(en)
|
1984-04-20 |
1990-10-23 |
Genentech, Inc. |
Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
|
US4694778A
(en)
|
1984-05-04 |
1987-09-22 |
Anicon, Inc. |
Chemical vapor deposition wafer boat
|
DE3683980D1
(de)
|
1985-04-12 |
1992-04-02 |
Genetics Inst |
Neue prokoagulierungsproteine.
|
US4745055A
(en)
|
1985-05-07 |
1988-05-17 |
California Biotechnology Inc. |
Fused protein for enzyme immunoassay system
|
EP0253870B1
(en)
|
1986-01-03 |
1993-03-31 |
Genetics Institute, Inc. |
Method for producing factor viii:c-type proteins
|
US5595886A
(en)
|
1986-01-27 |
1997-01-21 |
Chiron Corporation |
Protein complexes having Factor VIII:C activity and production thereof
|
US5543502A
(en)
|
1986-06-24 |
1996-08-06 |
Novo Nordisk A/S |
Process for producing a coagulation active complex of factor VIII fragments
|
CA1340456C
(en)
|
1986-07-07 |
1999-03-23 |
Hubert J.P. Schoemaker |
Chimeric rodent/human immunoglobulins specific for tumor-associated antigens
|
NO873164L
(no)
|
1986-07-30 |
1988-02-01 |
Teijin Ltd |
Muse-humane kimaere antistoffer.
|
IL84285A
(en)
|
1986-10-27 |
1993-03-15 |
Int Genetic Engineering |
Chimeric antibody with specificity to human tumor antigen
|
GB8626412D0
(en)
|
1986-11-05 |
1986-12-03 |
Clark M R |
Antibodies
|
CA1339445C
(en)
|
1986-11-12 |
1997-09-09 |
The General Hospital Corporation |
Recombinant hybrid immunoglobulin molecules and method of use
|
US4912040A
(en)
|
1986-11-14 |
1990-03-27 |
Genetics Institute, Inc. |
Eucaryotic expression system
|
GB8704647D0
(en)
*
|
1987-02-27 |
1987-04-01 |
Guy S & St Thomas S Hospitals |
Vaccine
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
CA1331157C
(en)
|
1987-04-06 |
1994-08-02 |
Randal J. Kaufman |
Method for producing factor viii:c-type proteins
|
US6060447A
(en)
|
1987-05-19 |
2000-05-09 |
Chiron Corporation |
Protein complexes having Factor VIII:C activity and production thereof
|
US6346513B1
(en)
|
1987-06-12 |
2002-02-12 |
Baxter Trading Gmbh |
Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
|
US5171844A
(en)
|
1987-06-12 |
1992-12-15 |
Gist-Brocades N.W. |
Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
|
DE3720246A1
(de)
|
1987-06-19 |
1988-12-29 |
Behringwerke Ag |
Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
|
US5892019A
(en)
|
1987-07-15 |
1999-04-06 |
The United States Of America, As Represented By The Department Of Health And Human Services |
Production of a single-gene-encoded immunoglobulin
|
FR2619314B1
(fr)
|
1987-08-11 |
1990-06-15 |
Transgene Sa |
Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
|
US4994371A
(en)
|
1987-08-28 |
1991-02-19 |
Davie Earl W |
DNA preparation of Christmas factor and use of DNA sequences
|
US6780613B1
(en)
|
1988-10-28 |
2004-08-24 |
Genentech, Inc. |
Growth hormone variants
|
US5004803A
(en)
|
1988-11-14 |
1991-04-02 |
Genetics Institute, Inc. |
Production of procoagulant proteins
|
US5175384A
(en)
|
1988-12-05 |
1992-12-29 |
Genpharm International |
Transgenic mice depleted in mature t-cells and methods for making transgenic mice
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
WO1990009800A1
(en)
|
1989-02-21 |
1990-09-07 |
Washington University |
Modified forms of reproductive hormones
|
US5122614A
(en)
|
1989-04-19 |
1992-06-16 |
Enzon, Inc. |
Active carbonates of polyalkylene oxides for modification of polypeptides
|
SE465222C5
(sv)
|
1989-12-15 |
1998-02-10 |
Pharmacia & Upjohn Ab |
Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
DE69120146T2
(de)
|
1990-01-12 |
1996-12-12 |
Cell Genesys Inc |
Erzeugung xenogener antikörper
|
US5595732A
(en)
|
1991-03-25 |
1997-01-21 |
Hoffmann-La Roche Inc. |
Polyethylene-protein conjugates
|
US5846951A
(en)
|
1991-06-06 |
1998-12-08 |
The School Of Pharmacy, University Of London |
Pharmaceutical compositions
|
US5756096A
(en)
|
1991-07-25 |
1998-05-26 |
Idec Pharmaceuticals Corporation |
Recombinant antibodies for human therapy
|
IE922437A1
(en)
|
1991-07-25 |
1993-01-27 |
Idec Pharma Corp |
Recombinant antibodies for human therapy
|
FR2686899B1
(fr)
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
ATE244763T1
(de)
|
1992-02-11 |
2003-07-15 |
Cell Genesys Inc |
Erzielen von homozygotem durch zielgerichtete genetische ereignisse
|
US5364771A
(en)
|
1992-04-07 |
1994-11-15 |
Emory University |
Hybrid human/porcine factor VIII
|
US5859204A
(en)
|
1992-04-07 |
1999-01-12 |
Emory University |
Modified factor VIII
|
US6376463B1
(en)
|
1992-04-07 |
2002-04-23 |
Emory University |
Modified factor VIII
|
US6005079A
(en)
|
1992-08-21 |
1999-12-21 |
Vrije Universiteit Brussels |
Immunoglobulins devoid of light chains
|
US6765087B1
(en)
|
1992-08-21 |
2004-07-20 |
Vrije Universiteit Brussel |
Immunoglobulins devoid of light chains
|
US5563045A
(en)
|
1992-11-13 |
1996-10-08 |
Genetics Institute, Inc. |
Chimeric procoagulant proteins
|
DK0693924T4
(da)
|
1993-02-22 |
2008-08-04 |
Abraxis Bioscience Inc |
Fremgangsmåde til (in vivo) levering af biologiske materialer og sammensætninger, der er egnede dertil
|
US5439686A
(en)
|
1993-02-22 |
1995-08-08 |
Vivorx Pharmaceuticals, Inc. |
Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
|
SE504074C2
(sv)
|
1993-07-05 |
1996-11-04 |
Pharmacia Ab |
Proteinberedning för subkutan, intramuskulär eller intradermal administrering
|
US5643575A
(en)
|
1993-10-27 |
1997-07-01 |
Enzon, Inc. |
Non-antigenic branched polymer conjugates
|
GB9422383D0
(en)
|
1994-11-05 |
1995-01-04 |
Wellcome Found |
Antibodies
|
US6030613A
(en)
|
1995-01-17 |
2000-02-29 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
US6485726B1
(en)
|
1995-01-17 |
2002-11-26 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
US6086875A
(en)
|
1995-01-17 |
2000-07-11 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of immunogens
|
US6096871A
(en)
|
1995-04-14 |
2000-08-01 |
Genentech, Inc. |
Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US5811524A
(en)
|
1995-06-07 |
1998-09-22 |
Idec Pharmaceuticals Corporation |
Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
|
SE9503380D0
(sv)
|
1995-09-29 |
1995-09-29 |
Pharmacia Ab |
Protein derivatives
|
US6458563B1
(en)
|
1996-06-26 |
2002-10-01 |
Emory University |
Modified factor VIII
|
AU3968897A
(en)
|
1996-08-02 |
1998-02-25 |
Bristol-Myers Squibb Company |
A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
|
US5972674A
(en)
*
|
1996-08-26 |
1999-10-26 |
Signal Pharmaceuticals, Inc. |
Stimulus-inducible protein kinase complex and methods of use therefor
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
CA2225189C
(en)
|
1997-03-06 |
2010-05-25 |
Queen's University At Kingston |
Canine factor viii gene, protein and methods of use
|
GB9722131D0
(en)
|
1997-10-20 |
1997-12-17 |
Medical Res Council |
Method
|
GB9723062D0
(en)
*
|
1997-10-31 |
1998-01-07 |
Cambridge Antibody Tech |
Improvements relating to antibodies and libraries thereof
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
ATE375365T1
(de)
|
1998-04-02 |
2007-10-15 |
Genentech Inc |
Antikörper varianten und fragmente davon
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
EP1105427A2
(en)
|
1998-08-17 |
2001-06-13 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
EP1006183A1
(en)
|
1998-12-03 |
2000-06-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Recombinant soluble Fc receptors
|
US6197526B1
(en)
*
|
1999-01-04 |
2001-03-06 |
Dyax Corp. |
Polypeptides for binding human factor VIII and fragments of human factor VIII
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
HUP0104865A3
(en)
|
1999-01-15 |
2004-07-28 |
Genentech Inc |
Polypeptide variants with altered effector function
|
US6703491B1
(en)
|
1999-03-17 |
2004-03-09 |
Exelixis, Inc. |
Drosophila sequences
|
US20090087878A9
(en)
|
1999-05-06 |
2009-04-02 |
La Rosa Thomas J |
Nucleic acid molecules associated with plants
|
US6624289B1
(en)
|
1999-06-16 |
2003-09-23 |
Saint Louis University |
Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
|
US7109170B2
(en)
|
1999-06-16 |
2006-09-19 |
Saint Louis University |
Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
|
JP2003503426A
(ja)
|
1999-07-02 |
2003-01-28 |
ジェネンテック・インコーポレーテッド |
FVIIaアンタゴニスト
|
WO2001004287A1
(en)
|
1999-07-07 |
2001-01-18 |
Maxygen Aps |
A method for preparing modified polypeptides
|
AT411997B
(de)
|
1999-09-14 |
2004-08-26 |
Baxter Ag |
Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
|
EP2975127A1
(en)
*
|
1999-10-29 |
2016-01-20 |
GlaxoSmithKline Biologicals SA |
Neisserial antigenic peptides
|
DE60138364D1
(de)
|
2000-02-11 |
2009-05-28 |
Bayer Healthcare Llc |
Gerinnungsfaktor vii oder viia konjugate
|
EP1276849A4
(en)
|
2000-04-12 |
2004-06-09 |
Human Genome Sciences Inc |
ALBUMIN FUSION PROTEINS
|
US6905683B2
(en)
|
2000-05-03 |
2005-06-14 |
Novo Nordisk Healthcare A/G |
Human coagulation factor VII variants
|
EP1282693B1
(en)
|
2000-05-03 |
2010-10-20 |
Novo Nordisk Health Care AG |
Human coagulation factor vii variants
|
WO2001087922A2
(en)
|
2000-05-16 |
2001-11-22 |
Lipoxen Technologies Limited |
Derivatisation of proteins in aqueous solution
|
AU2001270609A1
(en)
|
2000-06-30 |
2002-01-14 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
Heterodimeric fusion proteins
|
US6423826B1
(en)
|
2000-06-30 |
2002-07-23 |
Regents Of The University Of Minnesota |
High molecular weight derivatives of vitamin K-dependent polypeptides
|
US20030211094A1
(en)
|
2001-06-26 |
2003-11-13 |
Nelsestuen Gary L. |
High molecular weight derivatives of vitamin k-dependent polypeptides
|
US20030138769A1
(en)
*
|
2000-08-16 |
2003-07-24 |
Birkett Ashley J. |
Immunogenic HBc chimer particles having enhanced stability
|
EP1332209B1
(en)
|
2000-09-08 |
2009-11-11 |
Universität Zürich |
Collections of repeat proteins comprising repeat modules
|
HUP0301246A3
(en)
|
2000-09-13 |
2005-12-28 |
Novo Nordisk Healthcare Ag |
Human coagulation factor vii variants
|
AU2002218029A1
(en)
|
2000-11-09 |
2002-05-21 |
The Scripps Research Institute |
Modified factor viia
|
AU2002226028A1
(en)
|
2000-11-14 |
2002-05-27 |
Board Of Regents, Unversity Of Texas Systems |
Mutant human factor ix with an increased resistance to inhibition by heparin
|
GB0029407D0
(en)
|
2000-12-01 |
2001-01-17 |
Affitech As |
Product
|
EP2341060B1
(en)
|
2000-12-12 |
2019-02-20 |
MedImmune, LLC |
Molecules with extended half-lives, compositions and uses thereof
|
US6888319B2
(en)
|
2001-03-01 |
2005-05-03 |
Palomar Medical Technologies, Inc. |
Flashlamp drive circuit
|
CA2440582A1
(en)
|
2001-03-09 |
2002-10-03 |
Dyax Corp. |
Serum albumin binding moieties
|
EP1373493B1
(en)
|
2001-03-22 |
2013-07-31 |
Novo Nordisk Health Care AG |
Coagulation factor vii derivative
|
US20040106794A1
(en)
|
2001-04-16 |
2004-06-03 |
Schering Corporation |
3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
|
US20040254106A1
(en)
|
2001-09-04 |
2004-12-16 |
Carr Francis J. |
Modified factor ix
|
ATE532858T1
(de)
|
2001-09-27 |
2011-11-15 |
Novo Nordisk Healthcare Ag |
Menschliche gerinnungsfaktor-vii-polypeptide
|
ES2288900T3
(es)
|
2001-10-05 |
2008-02-01 |
Affimed Therapeutics Ag |
Anticuerpo de origen humano para inhibir la agregacion de trombocitos.
|
US7125843B2
(en)
|
2001-10-19 |
2006-10-24 |
Neose Technologies, Inc. |
Glycoconjugates including more than one peptide
|
US7265084B2
(en)
|
2001-10-10 |
2007-09-04 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
US7265085B2
(en)
|
2001-10-10 |
2007-09-04 |
Neose Technologies, Inc. |
Glycoconjugation methods and proteins/peptides produced by the methods
|
NZ532027A
(en)
|
2001-10-10 |
2008-09-26 |
Neose Technologies Inc |
Remodeling and glycoconjugation of peptides
|
US7795210B2
(en)
|
2001-10-10 |
2010-09-14 |
Novo Nordisk A/S |
Protein remodeling methods and proteins/peptides produced by the methods
|
FR2831170B1
(fr)
|
2001-10-19 |
2004-03-19 |
Inst Nat Sante Rech Med |
Proteines c modifiees activables directement par la thrombine
|
KR101271635B1
(ko)
|
2001-12-21 |
2013-06-12 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
알부민 융합 단백질
|
US20080194481A1
(en)
|
2001-12-21 |
2008-08-14 |
Human Genome Sciences, Inc. |
Albumin Fusion Proteins
|
EP2277889B1
(en)
|
2001-12-21 |
2014-07-09 |
Human Genome Sciences, Inc. |
Fusion proteins of albumin and interferon beta
|
IL162604A0
(en)
*
|
2002-01-03 |
2005-11-20 |
Yissum Res Dev Co |
Conformationally constrained c-backbone cyclic peptides
|
EP1339006A1
(en)
*
|
2002-02-14 |
2003-08-27 |
AgeLab Pharma GmbH |
Method for the detection of a functional protein sequence and an apparatus therefor
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
US20040018557A1
(en)
|
2002-03-01 |
2004-01-29 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US20030170850A1
(en)
*
|
2002-03-09 |
2003-09-11 |
Cardone Michael H. |
Cell-based screening methods
|
AU2002316574B2
(en)
|
2002-03-15 |
2008-05-01 |
Brandeis University |
Central airway administration for systemic delivery of therapeutics
|
NZ536340A
(en)
|
2002-04-30 |
2006-09-29 |
Maxygen Holdings Ltd |
Factor VII or VIIa polypeptide variants with N-glycosylation
|
EP1534335B9
(en)
|
2002-08-14 |
2016-01-13 |
Macrogenics, Inc. |
Fcgammariib-specific antibodies and methods of use thereof
|
JP4597678B2
(ja)
|
2002-09-25 |
2010-12-15 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
ヒト凝固因子viiポリペプチド
|
BRPI0314814C1
(pt)
|
2002-09-27 |
2021-07-27 |
Xencor Inc |
anticorpo compreendendo uma variante de fc
|
PT1562972E
(pt)
|
2002-10-15 |
2010-11-10 |
Facet Biotech Corp |
Alteração de afinidades de ligação ao fcrn ou semi-vidas séricas de anticorpos por mutagénese
|
GB2395337B
(en)
|
2002-11-14 |
2005-12-28 |
Gary Michael Wilson |
Warning Unit
|
EP2368578A1
(en)
|
2003-01-09 |
2011-09-28 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
US7041635B2
(en)
|
2003-01-28 |
2006-05-09 |
In2Gen Co., Ltd. |
Factor VIII polypeptide
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
WO2004085633A1
(en)
*
|
2003-03-24 |
2004-10-07 |
The University Of Hong Kong |
A novel human virus causing severe acute respiratory syndrome (sars) and uses thereof
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
US7348004B2
(en)
|
2003-05-06 |
2008-03-25 |
Syntonix Pharmaceuticals, Inc. |
Immunoglobulin chimeric monomer-dimer hybrids
|
WO2005016974A1
(en)
|
2003-08-12 |
2005-02-24 |
Lipoxen Technologies Limited |
Sialic acid derivatives for protein derivatisation and conjugation
|
WO2005035003A2
(en)
*
|
2003-09-22 |
2005-04-21 |
Dihedron Corporation |
Compositions and methods for increasing drug efficiency
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
US7211559B2
(en)
|
2003-10-31 |
2007-05-01 |
University Of Maryland, Baltimore |
Factor VIII compositions and methods
|
WO2005077981A2
(en)
|
2003-12-22 |
2005-08-25 |
Xencor, Inc. |
Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
|
DE602005015542D1
(de)
|
2004-01-12 |
2009-09-03 |
Applied Molecular Evolution |
Varianten der fc-region
|
EP1718667B1
(en)
|
2004-02-23 |
2013-01-09 |
Genentech, Inc. |
Heterocyclic self-immolative linkers and conjugates
|
EP2053062A1
(en)
|
2004-03-24 |
2009-04-29 |
Xencor, Inc. |
Immunoglobin variants outside the Fc region
|
WO2005123780A2
(en)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
WO2006085967A2
(en)
|
2004-07-09 |
2006-08-17 |
Xencor, Inc. |
OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
|
EP1919950A1
(en)
|
2004-07-15 |
2008-05-14 |
Xencor, Inc. |
Optimized fc variants
|
WO2006047350A2
(en)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
PL1824988T3
(pl)
|
2004-11-12 |
2018-01-31 |
Bayer Healthcare Llc |
Ukierunkowana na miejsce modyfikacja czynnika VIII
|
US20100056392A1
(en)
*
|
2005-06-15 |
2010-03-04 |
Matthew Greving |
Microstructure and microdomain microarrays, methods of making same and uses thereof
|
US20090041744A1
(en)
|
2005-06-17 |
2009-02-12 |
Novo Nordisk Healthcare A/G |
Dimeric and Multimeric FVIIa Compounds
|
KR20080071119A
(ko)
|
2005-08-12 |
2008-08-01 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
알부민 융합 단백질
|
US7855279B2
(en)
|
2005-09-27 |
2010-12-21 |
Amunix Operating, Inc. |
Unstructured recombinant polymers and uses thereof
|
CA2635968A1
(en)
|
2006-01-04 |
2007-07-12 |
Do-Coop Technologies Ltd. |
Cryoprotective compositions and methods of using same
|
US8048848B2
(en)
|
2006-02-03 |
2011-11-01 |
Prolor Biotech Ltd. |
Long-acting interferons and derivatives thereof and methods thereof
|
CA2644712C
(en)
|
2006-03-06 |
2016-09-13 |
Amunix, Inc. |
Unstructured recombinant polymers and uses thereof
|
WO2007104146A1
(en)
|
2006-03-13 |
2007-09-20 |
Tir Technology Lp |
Adaptive control apparatus and method for a solid-state lighting system
|
CA2646508A1
(en)
|
2006-03-17 |
2007-09-27 |
Biogen Idec Ma Inc. |
Stabilized polypeptide compositions
|
EP2423307A1
(en)
|
2006-06-19 |
2012-02-29 |
Catalyst Biosciences, Inc. |
Modified coagulation factor IV polypeptides and use thereof for treatment
|
EP2068905A4
(en)
|
2006-09-14 |
2009-12-30 |
Human Genome Sciences Inc |
ALBUM INFUSION PROTEINS
|
US7700734B2
(en)
|
2007-01-09 |
2010-04-20 |
Shu-Wha Lin |
Recombinant human factor IX and use thereof
|
JP2008289374A
(ja)
*
|
2007-05-22 |
2008-12-04 |
Kyushu Univ |
タンパク質キナーゼの新規基質ポリペプチド
|
WO2008157380A2
(en)
*
|
2007-06-15 |
2008-12-24 |
Adherex Technologies Inc. |
Chemically modified cyclic peptides containing cell adhesion recognition (car) sequences and uses therefor
|
ATE502114T1
(de)
|
2007-06-21 |
2011-04-15 |
Univ Muenchen Tech |
Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
|
KR20100058541A
(ko)
|
2007-08-15 |
2010-06-03 |
아뮤닉스 인코포레이티드 |
생물학적 활성 폴리펩티드의 특성을 변경하기 위한 조성물 및 방법
|
EP2209487A4
(en)
|
2007-10-15 |
2012-06-20 |
Univ North Carolina |
VARIANTS OF HUMAN FACTOR IX WITH EXTENDED HALF-TIME
|
TWI465247B
(zh)
|
2008-04-11 |
2014-12-21 |
Catalyst Biosciences Inc |
經修飾的因子vii多肽和其用途
|
RU2010146387A
(ru)
|
2008-04-16 |
2012-05-27 |
БАЙЕР ХЕЛСКЕР ЛЛСи (US) |
Модифицированные полипептиды фактора ix и их применение
|
CA2721362A1
(en)
|
2008-04-16 |
2009-11-19 |
Bayer Healthcare Llc |
Site-directed modification of factor ix
|
TWI573806B
(zh)
|
2008-04-17 |
2017-03-11 |
巴克斯歐塔公司 |
生物活性胜肽
|
EP2268807A2
(en)
|
2008-04-21 |
2011-01-05 |
Novo Nordisk A/S |
Hyperglycosylated human coagulation factor ix
|
US20090305297A1
(en)
*
|
2008-06-06 |
2009-12-10 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
EP2347263B1
(en)
|
2008-10-03 |
2017-05-17 |
President and Fellows of Harvard College |
Methods, compositions and kits for high throughput kinase activity screening using mass spectrometry and stable isotopes
|
CN116925238A
(zh)
|
2009-02-03 |
2023-10-24 |
阿穆尼克斯制药公司 |
延伸重组多肽和包含该延伸重组多肽的组合物
|
US8680050B2
(en)
|
2009-02-03 |
2014-03-25 |
Amunix Operating Inc. |
Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
|
US8703717B2
(en)
|
2009-02-03 |
2014-04-22 |
Amunix Operating Inc. |
Growth hormone polypeptides and methods of making and using same
|
CA2764108A1
(en)
|
2009-06-08 |
2010-12-16 |
Amunix Operating Inc. |
Glucose-regulating polypeptides and methods of making and using same
|
EP3278813A1
(en)
|
2009-06-08 |
2018-02-07 |
Amunix Operating Inc. |
Growth hormone polypeptides and methods of making and using same
|
CN102741422B
(zh)
|
2009-08-24 |
2016-06-08 |
阿穆尼克斯运营公司 |
凝血因子ⅶ组合物及其制备和使用方法
|
WO2011028344A2
(en)
|
2009-08-25 |
2011-03-10 |
Amunix Operating Inc. |
Interleukin-1 receptor antagonist compositions and methods of making and using same
|
CN102791285A
(zh)
|
2009-12-06 |
2012-11-21 |
比奥根艾迪克依蒙菲利亚公司 |
因子VIII-Fc嵌合多肽和杂交多肽及其使用方法
|
EP2576614A4
(en)
*
|
2010-05-24 |
2013-11-13 |
Phosimmune Inc |
MHC CLASS I PHOSPHOPEPTIDES FOR CANCER IMMUNOTHERAPY AND DIAGNOSIS
|
WO2012006623A1
(en)
|
2010-07-09 |
2012-01-12 |
Biogen Idec Hemophilia Inc. |
Systems for factor viii processing and methods thereof
|
MX2013000301A
(es)
|
2010-07-09 |
2013-05-09 |
Biogen Idec Hemophilia Inc |
Factores quimericos de coagulacion.
|
CA2868398A1
(en)
|
2012-04-02 |
2013-10-10 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of cosmetic proteins and peptides
|
JP2015521589A
(ja)
*
|
2012-06-08 |
2015-07-30 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
プロコアグラント化合物
|
AU2013270683A1
(en)
*
|
2012-06-08 |
2014-12-11 |
Biogen Ma Inc. |
Chimeric clotting factors
|